MDR targets emerging opportunities in which latent value awaits realization through the integration of divergent technology in healthcare

* There may be exceptions for early stage companies.  In addition, capital may be invested over more than one round of financing.

Target investments must articulate a clearly defined end-market. Our markets include, but are not limited to, neurology, cancer, cardiovascular, pulmonary, diabetes, urology, orthopaedic, nutrition and sports. 

Their business models share the following common characteristics:

• Scalable platform
• Sustainable competitive advantages
• Defensible intellectual property
• Ability to generate substantial free cash flow
• Management teams committed to creating shareholder value

Size of Investment:            $3 - $5 million *  

Investment Stage:              Early stage venture, small and mid-sized growth companies  

Ownership:                        Majority and minority

Geography:                        United States (primarily) and Europe 

Holding Period:                  2 - 5 years 

EMPOWERING  ENTREPRENEURS